Inkluder alle CSL Behrings regionale hjemmesider

CSL Behring worldwide

Denne hjemmeside anvender cookies

Du accepterer brugen af cookies ved at klikke videre på siden eller klikke OK.
Du finder information om cookies, hvilke vi anvender og hvorfor vi gør brug af dem ved at klikke her

Hos CSL Behring føler vi en forpligtelse til at forbedre livskvaliteten hos patienter med alvorlige sygdomme over hele verden. Vi fremstiller produkter med humant plasma og har eget produktionsapparat.

2016/17 CSL Behring Facts

Sales $5.8 Billion

CSL Behring Fact Sheet Pie Charts

CSL Behring, a member of the CSL Group of companies, is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies to treat people with life-threatening medical conditions.

We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge, and support future medical research.

Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop, and dependably deliver innovations that patients and providers want.

CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), is headquartered in Melbourne, Australia.

For more information visit, and follow us on (@CSLBehring), Bio Blog, and

16,000+ employees worldwide

Operational Headquarters
King of Prussia, Pennsylvania, USA

Plasma Collection
CSL Plasma is one of the world’s largest plasma collection organizations. The company operates more than 170 collection centers in the United States and Europe. Headquarters are in Boca Raton, Florida. Testing laboratories are located in the United States and Germany.

Bern, Switzerland; Marburg, Germany; Broadmeadows, Australia; Kankakee, Illinois, USA; Wuhan, China

Therapeutic Areas

Immunodeficiency and autoimmune diseases, such as primary immune deficiency, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura and Guillain-Barré syndrome, and to prevent hemolytic disease of the newborn and cytomegalovirus infection in patients following solid organ transplant

Coagulation or bleeding disorders, including hemophilia and von Willebrand disease

Alpha-1 antitrypsin deficiency (hereditary emphysema), hereditary angioedema and for warfarin reversal, wound healing, shock, burns, sepsis and during surgery

© 2018 CSL Behring